Pfizers Rituxan biosimilar bags FDA approval

The treatment has been approved in adult patients with non-Hodgkins lymphoma (NHL), chronic lymphocytic leukemia (CLL), and granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The approval was based on the review of a comprehensive data package, which demonstrated biosimilarity of Ruxience to Rituxan, including results from the REFLECTIONS B3281006 clinical comparative study, which evaluated the efficacy, safety and immunogenicity, pharmacokinetics and pharmacodynamics of the biosimilar and found no clinically meaningful differences in safety or efficacy in patients with CD20-positive, low tumour burden follicular lymphoma.

Upload Company Info



Chemxpert Demo Video


Dataset Sample


Chemical Name

Synonyms

Molecular Formula

Molecular Weight


To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Innovator

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Market Status

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Indication

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Dataset Sample


Product Name Therapeutic Segment

To Access this information please pay by using "Pay & Download" button.

Pay & Download

To Access this information please pay by using "Pay & Download" button.

Pay & Download

Thank you for your enquiry

Your product will be updated soon in our database


Submit Your Query



Select Any Option



Page loaded in 0.001232 seconds